Kevin Kalinsky, MD, MS

Experts from Emory Winship Cancer Institute discuss how the FDA approval of sacituzumab govitecan will impact the treatment of breast cancer.

“Nonetheless, we saw tremendous benefits for these patients, patients who didn’t benefit from other treatments, and it was exciting to be involved with this early research.”

Kevin Kalinsky, MD, MS, spoke about future studies following results from the phase 2 MAINTAIN trial of ribociclib with or without endocrine therapy and after progression on a CDK4/6 inhibitor for patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

The MAINTAIN trial was designed to assess endocrine therapy with or without ribociclib after progression on a CDK4/6 inhibitor in patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

Implications for using the Oncotype DX Breast Recurrence Score to help tailor therapy for patients with HR-positive, HER2-negative breast cancer based on data demonstrated in the TAILORx and RxPONDER studies.

A discussion on the types of information provided by genetic tests and genomic assays and recommendations for use in HR-positive breast cancer.

The value of utilizing a genomic test to help guide decisions for adjuvant therapy for HR-positive breast cancer.

Kevin Kalinsky, MD, MS, of Emory Winship Cancer Institute, discusses treatment options for HR-positive/HER2-negative breast cancer and comments on the evolving role of genomic testing in regard to treatment selection.

Dr Kevin Kalinsky describes when and for whom neoadjuvant therapy may be appropriate for the management of HR-positive breast cancer.

A recent study sought to evaluate the 21-gene Oncotype Dx Recurrence Score in nonmetastatic HR-positive, HER2-negative breast cancer.

The breast medical oncologist and researcher discussed how the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal, lymph node-positive, HR-positive, HER2-negative breast cancer.